|

Mogamulizumab Clinical Trials

8 actively recruiting trials across 7 locations

Also known as: Immunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer, KM8761, KW-0761, Mogamulizumab-kpkc, Poteligeo

Other1 trial

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
Phase 2

Birmingham, Alabama1 trial

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

University of Alabama at Birmingham

Phase 1

Scottsdale, Arizona1 trial

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Mayo Clinic

Phase 2

Stanford, California1 trial

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Stanford Cancer Center

Phase 2

New Haven, Connecticut1 trial

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale Cancer Center, Clinical Trials Office

Phase 2

Ann Arbor, Michigan1 trial

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

University of Michigan Comprehensive Cancer Center

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

Memorial Sloan Kettering at Basking Ridge (All protocol activities)

Phase 2

Columbus, Ohio1 trial

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.